Legend Biotech Corporation (LEGN) has released an update.
Legend Biotech USA Inc., a subsidiary of Legend Biotech Corporation, has entered a Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation to enhance their production capabilities for a cancer treatment drug, ciltacabtagene autoleucel. The agreement, effective from March 27, 2024, will run through the end of 2029 with provisions for early termination under specific conditions. It outlines commitments for manufacturing capacity, performance metrics, and financial terms, including tiered pricing and materials cost reimbursement.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
